Foghorn Therapeutics (FHTX) investor relations material

Strategic positioning and partnerships

• Focus on chromatin biology, targeting gene regulation implicated in up to 50% of tumors, with a broad impact across oncology and potential for expansion into other therapeutic areas.

• Major collaboration with Lilly includes $380 million upfront, 50/50 U.S. economic split on two lead programs, and potential for up to $1.3 billion in milestones.

• Well-funded with $167.6 million in cash as of June 2026, providing runway into the first half of 2028.

Pipeline and clinical development

• Lead asset FHD-909, a selective SMARCA2 inhibitor, is in Phase 1 for SMARCA4-mutant cancers, partnered with Lilly.

• Additional programs include selective degraders for EP300, CBP, and ARID1B, each targeting genetically defined cancer populations with high unmet need.

• EP300 and CBP degraders show high selectivity, improved tolerability, and efficacy in preclinical models, with INDs targeted for 2027.

• ARID1B degrader program addresses up to 5% of all solid tumors, with multiple binders showing nM affinity and selectivity.

Scientific innovation and differentiation

• Platform leverages deep mechanistic understanding of chromatin regulation, enabling drugging of previously undruggable targets.

• Synthetic lethality and lineage dependencies are exploited for precision targeting in cancer.

• Selective protein degradation and induced proximity approaches expand the therapeutic toolkit.